NBs remained visible in tumor vasculature on US imaging for up to 5 minutes post-injection, indicating short circulation time. Fluorescence imaging demonstrated strong binding to HER2-positive SKOV3 ovarian cancer cells and minimal binding to HER2-negative MDA-MB-231 cells, confirming targeted uptake. Here, ERBB2 is linked to ovarian cancer.